# Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz

> **NCT01458769** · PHASE1 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** C-10276
- **DRUG:** C-10276
- **DRUG:** C-10297
- **DRUG:** C-10299
- **DRUG:** C-10297
- **DRUG:** C-10299
- **DRUG:** C-10276
- **DRUG:** Reyataz®

## Key facts

- **NCT ID:** NCT01458769
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2013-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01458769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01458769, "Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01458769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*